Subunit vaccine against the seven serotypes of botulism

Infection and Immunity

Volumn 76, Issue 3, 2008, Pages 1314-1318

  Baldwin, Michael R ^a   Tepp, William H ^b   Przedpelski, Amanda ^a   Pier, Christina L ^b   Bradshaw, Marite ^b   Johnson, Eric A ^b   Barbieri, Joseph T ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b UNIVERSITY OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM NEUROTOXIN G; BOTULINUM TOXIN; BOTULINUM TOXIN A; BOTULINUM TOXIN B; BOTULINUM TOXIN E; BOTULINUM TOXIN F; GANGLIOSIDE GT 1B; METALLOPROTEINASE; RECEPTOR PROTEIN; SUBUNIT VACCINE; UNCLASSIFIED DRUG; ZINC METALLOPROTEASE; ANTITOXIN; BACTERIUM ANTIBODY; GANGLIOSIDE; GANGLIOSIDE, GT1; RECOMBINANT VACCINE;

ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ARTICLE; BOTULISM; DISULFIDE BOND; ESCHERICHIA COLI; FEMALE; HEAVY CHAIN; IMMUNIZATION; IMMUNOREACTIVITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ENGINEERING; PROTEIN EXPRESSION; PROTEIN PURIFICATION; SEROTYPE; ANIMAL; BIOSYNTHESIS; BLOOD; GENETICS; IMMUNOLOGY; INSTITUTE FOR CANCER RESEARCH MOUSE; ISOLATION AND PURIFICATION; METABOLISM; SERODIAGNOSIS;

ANIMALS; ANTIBODIES, BACTERIAL; ANTITOXINS; BOTULINUM TOXINS; BOTULISM; ESCHERICHIA COLI; FEMALE; GANGLIOSIDES; MICE; MICE, INBRED ICR; NEUTRALIZATION TESTS; VACCINES, SUBUNIT; VACCINES, SYNTHETIC;

EID: 40749123001     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/IAI.01025-07     Document Type: Article

References (36)

1. Arnon, S. S., R. Schechter, T. V. Inglesby, D. A. Henderson, J. G. Bartlett, M. S. Ascher, E. Eitzen, A. D. Fine, J. Hauer, M. Layton, S. Lillibridge, M. T. Osterholm, T. O'Toole, G. Parker, T. M. Perl, P. K. Russell, D. L. Swerdlow, and K. Tonat. 2001. Botulinum toxin as a biological weapon: medical and public health management. JAMA 285:1059-1070.
2. Arnon, S. S., R. Schechter, S. E. Maslanka, N. P. Jewell, and C. L. Hatheway. 2006. Human botulism immune globulin for the treatment of infant botulism. N. Engl. J. Med. 354:462-471.
3. Baldwin, M. R., and J. T. Barbieri. 2007. Association of botulinum neurotoxin serotypes A and B with synaptic vesicle protein complexes. Biochemistry 46:3200-3210.
4. Baldwin, M. R., W. H. Tepp, C. L. Pier, M. Bradshaw, M. Ho, B. A. Wilson, R. B. Fritz, E. A. Johnson, and J. T. Barbieri. 2005. Characterization of the antibody response to the receptor binding domain of botulinum neurotoxin serotypes A and E. Infect. Immun. 73:6998-7005.
5. Boles, J., M. West, V. Montgomery, R. Tammariello, M. L. Pitt, P. Gibbs, L. Smith, and R. D. LeClaire. 2006. Recombinant C fragment of botulinum neurotoxin B serotype (rBoNTB (HC)) immune response and protection in the rhesus monkey. Toxicon 47:877-884.
6. Byrne, M. P., and L. A. Smith. 2000. Development of vaccines for prevention of botulism. Biochimie 82:955-966.
7. Byrne, M. P., T. J. Smith, V. A. Montgomery, and L. A. Smith. 1998. Purification, potency, and efficacy of the botulinum neurotoxin type A binding domain from Pichia pastoris as a recombinant vaccine candidate. Infect. Immun. 66:4817-4822.
8. Casadevall, A. 2002. Passive antibody administration (immediate immunity) as a specific defense against biological weapons. Emerg. Infect. Dis. 8:833-841.
9. CDC. 1998. Laboratory registration and select agent transfer tracking system. 42 CFR 72. Appendix A: CDC guidance and information on microorganisms, A-1-A-45. U.S. Department of Health and Human Services, Washington, DC.
10. Chai, Q., J. W. Arndt, M. Dong, W. H. Tepp, E. A. Johnson, E. R. Chapman, and R. C. Stevens. 2006. Structural basis of cell surface receptor recognition by botulinum neurotoxin B. Nature 444:1096-1100.
11. Clayton, M. A., J. M. Clayton, D. R. Brown, and J. L. Middlebrook. 1995. Protective vaccination with a recombinant fragment of Clostridium botulinum neurotoxin serotype A expressed from a synthetic gene in Escherichia coli. Infect. Immun. 63:2738-2742.
12. Dong, M., D. A. Richards, M. C. Goodnough, W. H. Tepp, E. A. Johnson, and E. R. Chapman. 2003. Synaptotagmins I and II mediate entry of botulinum neurotoxin B into cells. J. Cell Biol. 162:1293-1303.
13. Dong, M., F. Yeh, W. H. Tepp, C. Dean, E. A. Johnson, R. Janz, and E. R. Chapman. 2006. SV2 is the protein receptor for botulinum neurotoxin A. Science 312:592-596.
14. Fiock, M. A., M. A. Cardella, and N. F. Gearinger. 1963. Studies on immunity to toxins of Clostridium botulinum. IX. Immunologic response of man to purified pentavalent ABCDE botulinum toxoid. J. Immunol. 90:697-702.
15. Jin, R., A. Rummel, T. Binz, and A. T. Brunger. 2006. Botulinum neurotoxin B recognizes its protein receptor with high affinity and specificity. Nature 444:1092-1095.
16. Kozaki, S., Y. Kamata, S. Watarai, T. Nishiki, and S. Mochida. 1998. Ganglioside GT1b as a complementary receptor component for Clostridium botulinum neurotoxins. Microb. Pathog. 25:91-99.
17. Kubota, T., T. Watanabe, N. Yokosawa, K. Tsuzuki, T. Indoh, K. Moriishi, K. Sanda, Y. Maki, K. Inoue, and N. Fujii. 1997. Epitope regions in the heavy chain of Clostridium botulinum type E neurotoxin recognized by monoclonal antibodies. Appl. Environ. Microbiol. 63:1214-1218.
18. Lee, J. C., H. J. Hwang, Y. Sakaguchi, Y. Yamamoto, H. Arimitsu, T. Tsuji, T. Watanabe, T. Ohyama, T. Tsuchiya, and K. Oguma. 2007. C terminal half fragment (50 kDa) of heavy chain components of Clostridium botulinum type C and D neurotoxins can be used as an effective vaccine. Microbiol. Immunol. 51:445-455.
19. Lee, J. S., J. L. Groebner, A. G. Hadjipanayis, D. L. Negley, A. L. Schmaljohn, S. L. Welkos, L. A. Smith, and J. F. Smith. 2006. Multiagent vaccines vectored by Venezuelan equine encephalitis virus replicon elicits immune responses to Marburg virus and protection against anthrax and botulinum neurotoxin in mice. Vaccine 24:6886-6892.
20. Lee, J. S., P. Pushko, M. D. Parker, M. T. Dertzbaugh, L. A. Smith, and J. F. Smith. 2001. Candidate vaccine against botulinum neurotoxin serotype A derived from a Venezuelan equine encephalitis virus vector system. Infect. Immun. 69:5709-5715.
21. Levy, R., C. M. Forsyth, S. L. LaPorte, I. N. Geren, L. A. Smith, and J. D. Marks. 2007. Fine and domain-level epitope mapping of botulinum neurotoxin type A neutralizing antibodies by yeast surface display. J. Mol. Biol. 365:196-210.
22. Mahrhold, S., A. Rummel, H. Bigalke, B. Davletov, and T. Binz. 2006. The synaptic vesicle protein 2C mediates the uptake of botulinum neurotoxin A into phrenic nerves. FEBS Lett. 580:2011-2014.
23. Marks, J. D. 2004. Deciphering antibody properties that lead to potent botulinum neurotoxin neutralization. Mov. Disord. 19(Suppl. 8):S101-S108.
24. Montecucco, C., O. Rossetto, and G. Schiavo. 2004. Presynaptic receptor arrays for clostridial neurotoxins. Trends Microbiol. 12:442-446.
25. Montecucco, C., and G. Schiavo. 1995. Structure and function of tetanus and botulinum neurotoxins. Q. Rev. Biophys. 28:423-472.
26. Montecucco, C., and G. Schiavo. 1993. Tetanus and botulism neurotoxins: a new group of zinc proteases. Trends Biochem. Sci. 18:324-327.
27. Nowakowski, A., C. Wang, D. B. Powers, P. Amersdorfer, T. J. Smith, V. A. Montgomery, R. Sheridan, R. Blake, L. A. Smith, and J. D. Marks. 2002. Potent neutralization of botulinum neurotoxin by recombinant oligoclonal antibody. Proc. Natl. Acad. Sci. USA 99:11346-11350.
28. Potter, K. J., W. Zhang, L. A. Smith, and M. M. Meagher. 2000. Production and purification of the heavy chain fragment C of botulinum neurotoxin, serotype A, expressed in the methylotrophic yeast Pichia pastoris. Protein Expr. Purif. 19:393-402.
29. Ravichandran, E., F. H. Al-Saleem, D. M. Ancharski, M. D. Elias, A. K. Singh, M. Shamim, Y. Gong, and L. L. Simpson. 2007. Trivalent vaccine against botulinum toxin serotypes A, B, and E that can be administered by the mucosal route. Infect. Immun. 75:3043-3054.
30. Scott, A. B. 2004. Development of botulinum toxin therapy. Dermatol. Clin. 22:131-133.
31. Smith, L. A., M. J. Jensen, V. A. Montgomery, D. R. Brown, S. A. Ahmed, and T. J. Smith. 2004. Roads from vaccines to therapies. Mov. Disord. 19(Suppl. 8):S48-S52.
32. Steinman, A., M. Chaffer, D. Elad, and N. Y. Shpigel. 2006. Quantitative analysis of levels of serum immunoglobulin G against botulinum neurotoxin type D and association with protection in natural outbreaks of cattle botulism. Clin. Vaccine Immunol. 13:862-868.
33. Takeda, M., H. Kasai, Y. Torii, M. Mukamoto, T. Kohda, K. Tsukamoto, and S. Kozaki. 2006. Protective effect of botulinum C/D mosaic toxoid against avian botulism. J. Vet. Med. Sci. 68:325-330.
34. Tavallaie, M., A. Chenal, D. Gillet, Y. Pereira, M. Manien, M. Gibert, S. Ralfestin, M. R. Popoff, and J. C. Marvaud. 2004. Interaction between the two subdomains of the C-terminal part of the botulinum neurotoxin A is essential for the generation of protective antibodies. FEBS Lett. 572:299-306.
35. Tsukamoto, K., T. Kohda, M. Mukamoto, K. Takeuchi, H. Ihara, M. Saito, and S. Kozaki. 2005. Binding of Clostridium botulinum type C and D neurotoxins to ganglioside and phospholipid. Novel insights into the receptor for clostridial neurotoxins. J. Biol. Chem. 280:35164-35171.
36. Yang, G. H., K. S. Kim, H. W. Kim, S. T. Jeong, G. H. Huh, J. C. Kim, and H. H. Jung. 2004. Isolation and characterization of a neutralizing antibody specific to internalization domain of Clostridium botulinum neurotoxin type B. Toxicon 44:19-25.